← Back to headlines
GSK Advances mRNA Seasonal Flu Vaccine Into Phase 3 Clinical Trials
GlaxoSmithKline has moved its experimental messenger RNA seasonal influenza vaccine into late-stage clinical testing following promising early results. The advancement marks a significant step toward developing a next-generation flu shot with potentially improved efficacy and manufacturing speed.
Sources
Showing 0 of 2 sources
No articles available in your preferred languages.
2 articles available in other languages below.
Coverage Timeline
First report: seeking-alpha · 1 Sept, 06:33|Full coverage: 2 · 22m|Window: 22m
Left-leaningCenterRight-leaning
